Trade RAPP anytime, even after market hours
Regulated by
MAS
Trusted by
400,000+ users
Rapport Therapeutics, Inc. (RAPP) is trading at US$49.68, down 2.26% today as of Aug 28, 12:41 EDT. The company has a market capitalisation of US$2.31B. Over the past 52 weeks, RAPP has traded between US$14.11 and US$52.93. On Syfe you can trade RAPP with $0 commission and add it to your watchlist.
| Previous close | US$50.83 |
|---|---|
| Market cap | US$2.31B |
| 52-week range | US$14.11 – US$52.93 |
| Volume | 382.83K |
| Exchange | US |
Add to Watchlist
Set Price Alert
Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.
Year: 2024
William Blair Initiates Rapport Therapeutics at Outperform
Jul 28, 11:23 AM · MT Newswires
Leerink Partners Initiates Rapport Therapeutics at Outperform With $52 Price Target
Jun 24, 11:37 AM · MT Newswires
-- Earnings Flash (RAPP) Rapport Therapeutics, Inc. Reports Q1 Revenue $20.0M, vs. FactSet Est of $7.5M
May 7, 11:07 AM · MT Newswires
Rapport Therapeutics Insider Sold Shares Worth $695,823, According to a Recent SEC Filing
Apr 14, 8:21 PM · MT Newswires
Raymond James Initiates Rapport Therapeutics at Strong Buy
Apr 10, 11:21 AM · MT Newswires
Rapport Therapeutics, Inc. (RAPP) stock is trading at US$49.68, -2.26% from the previous close of US$50.83.
The market cap for Rapport Therapeutics, Inc. (RAPP) stock is approximately US$2.31B.
The 52-week high for Rapport Therapeutics, Inc. (RAPP) stock is US$52.93.
The 52-week low for Rapport Therapeutics, Inc. (RAPP) stock is US$14.11.
Rapport Therapeutics, Inc. (RAPP) does not currently pay a dividend.
Stay on top of RAPP
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
